VVF India Limited Vs Commissioner of C.E. & S.T (CESTAT Ahmedabad)
The case of VVF India Limited vs. Commissioner of C.E. & S.T. before the CESTAT Ahmedabad brings into focus the complexities involved in classifying products within the Central Excise Tariff Act, 1985. Specifically, the case examines whether products like the Suncros UVA Lotion/Gel/Hyclean Cream should be classified as medicaments or cosmetics. Additionally, the case addresses whether the extended period of limitation can be invoked in this context. This article delves into the details of the case, the arguments presented, and the final ruling by the tribunal.
Detailed Analysis
1. Classification Issue: Medicaments vs. Cosmetics
The core issue in this case is whether the products in question should be classified under Chapter Sub-Heading No. 3004 (medicaments) or Chapter Sub-Heading No. 3304 (cosmetics) of the Central Excise Tariff Act.
1.1. Appellant’s Argument
Shri Anand Nainawati, the learned counsel for the appellant, argued that the Suncros UVA Lotion/Gel/Hyclean Cream should be classified as a medicament. The key points in his argument include:
- Composition and Use: The product contains various USP/IP drugs and other chemicals intended to protect against UV rays that can lead to sunburn or skin cancer. The formulation is designed to offer comprehensive protection, aligning with the characteristics of a medicament rather than a cosmetic.
- Manufacturing License and Labeling: The product is manufactured under a drug manufacturing license, and the packaging indicates that it is to be sold only on the prescription of a registered medical practitioner. This labeling aligns with the requirements of the Drugs and Cosmetics Rules, 1945, which supports its classification as a medicament.
- Legal Precedents: The counsel cited several judgments to support the claim that the product’s classification as a medicament is consistent with past rulings. These include cases such as CCE v. Ciens Laboratories and Puma Ayurvedic Herbal (P) Ltd Vs CCE, among others.
1.2. Revenue’s Argument
